Ozekibart is a monoclonal antibody commercialized by Inhibrx, with a leading Phase II program in Chondrosarcoma. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of Ozekibart’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Ozekibart is expected to reach an annual total of $9 mn by 2037 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
INBRX-109 is under development for the treatment of metastatic or non-resectable solid tumors including sarcoma, Ewing sarcoma, malignant pleural mesothelioma, gastric adenocarcinoma, colorectal adenocarcinoma, metastatic adenocarcinoma of the pancreas and conventional chondrosarcoma for which it is administered through intravenous route. The drug candidate is a engineered tetravalent single domain antibody (sdAb)-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.
Inhibrx is a biotechnology company that discovers and develops biologic therapeutics for the treatment of cancer and infectious diseases. It is investigating INBRX-101, a recombinant human AAT-Fc fusion protein candidate for the treatment of AATD (alpha-1 antitrypsin deficiency); INBRX-109, an engineered tetravalent sdAb-based therapeutic candidate to treat cancer by activating DR5 (death receptor 5). The company is also evaluating INBRX-106 program against advanced or metastatic solid tumors; and INBRX-105 therapeutic candidate targeting patients with programmed death-ligand 1 (PD-L1) expressing tumors. It utilizes its proprietary sdAb (single-domain antibody) platform to develop biotherapeutics that interface with the biology of each target antigen by focusing on immune activation and mediating enhanced signaling. Inhibrx is headquartered in La Jolla, California, the US.
The company reported revenues of (US Dollars) US$7.2 million for the fiscal year ended December 2021 (FY2021), a decrease of 43.9% over FY2020. The operating loss of the company was US$76.6 million in FY2021, compared to an operating loss of US$67.4 million in FY2020. The net loss of the company was US$81.8 million in FY2021, compared to a net loss of US$76.1 million in FY2020. The company reported revenues of US$0.3 million for the third quarter ended September 2022, a decrease of 60.9% over the previous quarter.
For a complete picture of Ozekibart’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.